Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer

Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer DALLAS, April 18, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, today announced Aaron Osborne, MBBS, was appointed Chief Medical Officer and Chief Development Officer.

Read more